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Abstract
 w . X . x .  .The racemate compound MEN 11066 1- benzofuran-2-yl 4 -cyanophenyl methyl -1H-1,2,4-triazole and its enantiomers, q -MEN
 .11623 and y -MEN 11622, showed potent and selective aromatase activity on human placental microsomes. In addition, to better
evaluate their potency as anticancer drugs, the compounds were assayed on testosterone-induced cell proliferation to measure their ability
in inhibiting oestrogen-dependent tumour growth. Two different sublines originated from the human breast carcinoma MCF-7 were used.
 .  .One, named MCF-7 tumour aromatase TA , that had maintained its intrinsic aromatase activity, was more sensitive to estradiol or
 .  .testosterone-induced growth than the second subline named MCF-7 human placental aromatase hPA . The latter had been transfected
with the human placental aromatase cDNA, after recognizing that the parental cells had aromatase activity reduced to undetectable levels.
 .  .The MEN compounds completely reverted the testosterone-induced proliferation in both MCF-7 TA and MCF-7 hPA cells, while they
 .did not affect the estradiol-triggered proliferation as a proof of their specificity for aromatase enzyme. Interestingly, MCF-7 TA cells
 .were more susceptible to the effects of aromatase inhibitors than the MCF-7 hPA cell. These data suggest the efficacy of aromatase
inhibitors in breast cancer when the growth dependency from oestrogen is high and a relatively low aromatase activity may be extremely
important for tumour development. q 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
The presence of oestrogen in breast cancer cells is
considered to be a critical factor for growth of this type of
 .tumour Henderson and Canellos, 1980 . In premenopausal
women, the main source of oestrogen synthesis is the
ovary. After menopause, the principal sites of oestrogen
synthesis are peripheral tissues, such as fat, skin and
 .muscle Miller et al., 1990 . In these tissues, aromatase
cytochrome P-450, a microsomal enzyme, is the rate-limit-
ing step in the synthesis of oestrogen Tan and Muto,
.1986 . It has been shown that, in postmenopausal women,
the concentrations of circulating estrone and estradiol are
insufficient to saturate the breast cancer oestrogen recep-
tors and that intracellular concentrations of these hormones
) Corresponding author. Tel.: q39-06-91184463; fax: q39-06-
9100220.
 .E-mail address: pharmacology@menarini-ricerche.it C. Palma .
in breast cancer cells are )10-fold higher than in plasma
 .Kitawaki et al., 1992 . This suggests that oestrogen may
be directly produced by cancer cells and that blockade of
intratumoural aromatase may have drastic consequences on
tumour growth.
Several groups have demonstrated that about 60–70%
of breast carcinomas contain detectable quantities of aro-
matase Miller, 1986; Silva et al., 1989, Lipton et al.,
.1987 ; clinical evidence indicates that differences in dis-
ease outcome are associated with the presence or absence
 .of this enzyme activity Miller and O’Neill, 1987 . There-
fore, a role of the intratumoural aromatase in the develop-
ment of breast cancer has been postulated. For this reason,
aromatase inhibitors have been widely used in the treat-
ment of postmenopausal breast cancer patients and have
been reported to be effective in ameliorating the conditions
 .of 30–40% of such patients Santen, 1991; Brodie, 1991 .
Discovering new aromatase inhibitors is, therefore, of great
importance.
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In this study, we describe a new aromatase inhibitor, the
 w . Xracemate compound MEN 11066 1- benzofuran-2-yl 4 -
. x .cyanophenyl methyl -1 H-1,2,4-triazole , and its enan-
 .  .tiomers, q -MEN 11623 and y -MEN 11622, which
show selective and specific ability in blocking the activity
of human placental enzyme. In addition, the activity of
 X wthese compounds, in comparison with anastrozole 2,2 - 5-
 . x 1H-1,2,4-triazol-1-ylmethyl -1-3-phenylene bis 2 -methyl-
.propiononitrile , a third-generation, triazole-based aro-
matase inhibitor Buzdar et al., 1996; Harper-Wynne and
.Coombes, 1999 was assessed in the androgen-dependent
tumour cell proliferation as a model to prove the physio-
logical relevance of intratumoural aromatase and, there-
fore, to better evaluate the potential use of aromatase
inhibitors as anticancer drugs.
The oestrogen-dependent human breast cancer cell line,
MCF-7, was derived from a pleural effusion taken from a
 .patient with metastatic breast cancer Soule et al., 1973 .
Various MCF-7 sublines, with peculiar characteristics, have
been originated from the primary culture and, in addition,
transfected cell lines have been constructed. In this paper,
two MCF-7 sublines — the first one, named MCF-
 .  .7 tumour aromatase TA , has an intrinsic tumour aro-
matase activity and the second, named MCF-7 human
.  .placental aromatase hPA , obtained by transfection with
a human placental aromatase cDNA of an MCF-7 subline
 .with undetectable aromatase activity Zhou et al., 1990 —
have been characterized for their responsiveness to steroid
hormones and used to evaluate the potency of the new
aromatase inhibitors. The difference in the responses to
oestrogen and androgens of these tumour cells may add
new important information to the knowledge of breast
cancer development and, in particular, about the role of the
intrinsic intratumoural aromatase and the effects of its
inhibition.
2. Materials and methods
2.1. Drugs and reagents
 X w The aromatase inhibitors anastrozole 2,2 - 5- 1H-
. x 1,2,4-triazol-1 - ylmethyl - 1 -3-phenylene bis 2-methylpro-
.  w . Xpiononitrile , MEN 11066 1- benzofuran-2-yl 4 -
. x .  .cyanophenyl methyl -1H-1,2,4-triazole Fig. 1 were syn-
thesized at the Chemistry Department of Menarini
Ricerche, Pomezia, Italy. The synthesis of MEN 11066
yelded a 94% pure racemic mixture. The resolution of the
single enantiomers was achieved by preparative chiral
 .high-performance liquid chromatography HPLC , with a
 .Chiralcel OD stationary phase Okamoto et al., 1988 . The
labor-intensive chromatographic resolution was chosen be-
cause of the lack in the molecule of strong basic or acidic
groups that could make possible a fractional crystallization
with a chiral reagent. To purify single enantiomers, a
 .20 = 250 mm Chiralcel OD Daicel Chemical Ind.
 .  .Fig. 1. Chemical structures of MEN 11066, y -MEN 11622, q -MEN
11623 and anastrozole.
semipreparative column was used with repetitive HPLC
runs, loading 30 mg of racemic mixture in 1 ml eluent per
run. The eluent was 70r30 hexanerisopropyl alcohol
 .Mallinckrodt Baker , pumped at a flow rate of 4 mlrmin
with a Delta Prep 2000 chromatograph Waters, Milford,
.MA equipped with a Knauer RI Detector at 16= . The
 X  . .fast eluting enantiomer k s2.27y q -MEN 11623 was
obtained at 98.9% enantiomeric eccess; the slow eluting
 X  . .enantiomer k s2.63y y -MEN 11622 was obtained at
96.3% enantiomeric eccess. Then, the purified enantiomers
were dried under vacuum.
All the inhibitors were dissolved at a concentration of
10y2 M in ethanol and stored at y208C. These storage
conditions prevent the racemization of the enantimoners
for at least 6 months. Dilutions were then made in the
appropriate experimental buffers.
Androstenedione, estradiol, estrone, testosterone and ta-
moxifen were purchased from Sigma St. Louis, MO,
.USA .
w3 x w3 x1b- H androstenedione and 7b- H androstenedione
were purchased from NEN Life Science Products Boston,
.USA .
2.2. Enzyme preparations
Microsomes for the in vitro aromatase activity assay
were prepared from human full-term placentas. The minced
tissues were homogenized in 50 mM Tris–HCl buffer, pH
7.4, containing 10 mM phenylmethylsulfonylfluoride, us-
ing a Polytron PT 3000 homogenizer Kinematica,
.Switzerland ; the homogenate was centrifuged for 35 min
at 10,000=g and the supernatant was recentrifuged for 60
min at 105,000=g; the final pellet was resuspended in 0.5
volumes of the above buffer, aliquoted and stored at
y808C.
2.3. Aromatase acti˝ity on microsome preparation
The reaction mixture, containing the enzyme 2–4 mg
.of human placental microsomes , the substrate 1b-
w3 x  .H androstenedione 9–300 nM , the cofactor NADPH
 .  .0.5 mM and the inhibitors 1–10 nM or their vehicle, in
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a total volume of 200 ml of 50 mM Tris–HCl buffer, was
incubated at 378C. Ten minutes after the addition of pla-
cental microsomes, the reaction was stopped by adding
200 ml of 1 mM HgCl . Four hundred microlitres of 1%2
charcoal suspension were then added and the mixture was
centrifuged at 2000=g for 15 min. Four hundred mi-
crolitres of supernatant were placed into scintillation vials
 .containing 4 ml of Cytoscint ICN Biochemicals . Re-
leased tritiated water was counted by liquid scintillation
 .2200 CA counter, Packard Instruments, USA . K andm
V values were calculated by fitting the curves of reac-max
tion rate vs. substrate concentration by the nonlinear re-
 .gression program Ultrafit Biosoft, UK .
K values were obtained according to the Cheng andi
 .Prusoff 1973 equation for competitive inhibition: K si
w x  . 4 w xi r K rK y1 , where: i is the inhibitor concentra-p m
tion and K is the K value calculated in the presence ofp m
the inhibitor.
( )2.4. Culture of human breast carcinoma MCF-7 TA and
( )MCF-7 hPA cells
MCF-7 cells were a kind gift from Dr. F. Zunino,
Istituto Tumori, Milan, Italy. In our laboratory a subline
able to proliferate in the presence of testosterone was
selected and to indicate the presence of an intrinsic tumour
 .aromatase activity the cells were named MCF-7 TA . These
 .cells were routinely cultured in high glucose 4500 mgrl
Dulbecco’s modified Eagle medium containing 10% heat-
 .inactivated 658C, 30 min foetal bovine serum with 5 mM
HEPES, 2 mM L-glutamine, 100 Urml of penicillin and
100 mgrml of streptomycin at 378C in an atmosphere of
 .5% CO . The human breast carcinoma MCF-7 3 2 cells,2
transfected with human placental aromatase cDNA Zhou
.et al., 1990 were a kind gift from Dr. Shiuan Chen,
Beckman Research Institute of the City of Hope, Duarte,
 .CA, USA. We renamed these cells as MCF-7 hPA for
better comprehension. The cells were routinely maintained
 .in Eagle’s minimal essential medium MEM containing
10% heat-inactivated foetal bovine serum with 5 mM
HEPES, 2 mM L-glutamine, 600 mgrml G418 at 378C in
an atmosphere of 5% CO . All reagents were purchased2
 .from Gibco Laboratories Grand Island, NY .
2.5. Cell growth and DNA synthesis
To observe the effects of steroids on cell proliferation
and DNA synthesis, step-down conditions were used, ac-
complished by growing cells for 7 days in phenol red-free
MEM containing 10% dextran-coated charcoal stripped
 .foetal calf serum oestrogen-depleted medium with 5 mM
HEPES and 2 mM L-glutamine. After this 7-day growing
 .in oestrogen-depleted medium, MCF-7 TA and MCF-
 . 7 hPA were plated on 24-well tissue culture plates 2.5 or
4 4  .6=10 and 3 or 4=10 cellsrwell for MCF-7 TA and
 . .MCF-7 hPA , respectively in oestrogen-depleted medium
and left to adhere for 24 h. In the experiments, to assay the
steroid-dependent growth, the cells were incubated in oe-
strogen-depleted medium containing various concentra-
 .tions 0.0001–100 nM of estradiol, androstenendione,
testosterone or estrone. The incubation medium was re-
placed twice a week. Proliferation and DNA synthesis
were then measured at various time points as described
below. In the experiments, to assay the potency of aro-
matase inhibitors, the cells were stimulated with testos-
terone or androstenedione 100 nM in the absence or the
 .presence of various concentrations 0.001–100 nM of
anastrozole, MEN 11066, MEN 11623 or MEN 11622.
The incubation medium was replaced twice a week. The
cells were then counted after 12 or 13 days of stimulation
 .  .for MCF-7 TA and MCF-7 hPA , respectively.
In proliferation studies, at the end of each experimental
time, the medium was aspirated and the cells detached by
incubation for 15 min at 378C with 50 ml versene and 150
ml trypsin-EDTA per well. The cells were then diluted in
the vital colorant trypan blue and counted in a haemocy-
 .tometer counting chamber Newbauer .
For DNA synthesis evaluation, at the end of each
experimental time, the cells were pulsed for 1 h with 500
w3 x mlrwell of H methyl-thymidine specific activity, 82.5
Cirmmol, NEN-Du Pont De Nemours Italiana, Cologno
 . .Monzese MI , Italy at a concentration of 1 mCirml. At
the end of incubation, the cells were treated with 1 ml of
cold 5% trichloroacetic acid for 10 min at 48C. The acid
supernatant was removed and the cells were washed with
 .double-distilled H O three times, 2 ml each time . The2
cells were removed from each well with 0.5 ml of 0.1 N
NaOH and incubated for 15 min. Each sample was then
neutralized with 0.1 N HCl in the scintillation vials. The
radioactivity in the vials was quantified by a liquid scintil-
 .lation counter Packard, 2002 .
[3 ]2.6. Con˝ersion of H androstenedione by human breast
( ) ( )carcinoma MCF-7 TA and MCF-7 hPA cells: HPLC
analysis
 6.Cells approximately 5=10 , in the complete medium,
were seeded in 250 ml cell culture flask. After 72 h of
culture, cells were washed twice with phenol red-free
MEM and then incubated with 3 ml of phenol red-free
MEM containing 5 mM HEPES, 2 mM L-glutamine and
w3 x200 nM 7b- H androstenedione. After 7, 24 or 48 h of
incubation at 378C, incubation medium was transferred to
plastic tubes and stored at y308C until analysis. Cells
were detached by incubation for 15 min at 378C with
versene and trypsin-EDTA and were then diluted in the
vital colorant trypan blue and counted in a haemocytome-
 .ter counting chamber Newbauer .
 .Steroid extraction from the incubation medium 3 ml
was carried out with 5 ml of diethyl ether for three times;
the pooled ether extracts were brought to dryness under N2
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prior to redissolution with 70% acqueous methanol and
injection into the HPLC system.
The HPLC system consisted of a 126 model pump
 .Beckman Instruments, INC connected to a Supersphere
 .100 RP-18 reverse phase column E. Merk, Darmstadt
protected by its precolumn. UV absorbance at 214 nm was
monitored with a model 486 detection Waters Millipore,
.Milan, Italy . Radioactivity was analyzed by a Flo-
onerBeta Series A-200 radioactivity detector Radiomatic
.Instruments, USA , with 3:1 ratio of Ultima-Flo M cock-
 .tail Packard to mobile phase. Mobile phase was com-
posed of aqueous 0.1% trifluoroacetic acid, and aceto-
nitrile in the ratio 65r35 vrv. Flow rate was set at 0.8
mlrmin.
2.7. Data analysis
Statistical analysis of data was performed with one-way
 .analysis of variance ANOVA followed by Tukey test, if
not differently stated.
Curves of aromatase inhibitor activity on testosterone-
 .  .induced MCF-7 TA or MCF-7 hPA cell proliferation
were fitted using the computer program ALLFIT De Lean
.et al., 1978 that provides the IC values and related50
statistical analysis.
3. Results
3.1. Characterization of aromatase inhibitors on human
placental microsomes
The kinetic parameters for the aromatization of 1b-
w3 xH androstenedione by human placenta aromatase were:
K s5.1"0.4 nM and V s18"1 pmol of releasedm max
tritiated water per mg protein per min mean of three
.values"S.E. . When tested at increasing concentrations
from 1 to 10 nM, all the aromatase inhibitors produced
graded increases of K , but no significant variation ofm
V values. This indicates a competitive inhibition andmax
allowed calculation of the K values according to Chengi
 .  .Fig. 2. Effects of steroid hormones on human breast carcinoma MCF-7 TA cell proliferation. MCF-7 TA cells were plated at 25,000 cellsrwell and
 .stimulated in oestrogen depleted medium with various concentrations 0.0001–100 nM of estradiol, estrone, testosterone and androstenedione. Incubation
 .medium was replaced twice a week. Cells were counted in a haemocytometer counting chamber Newbauer after 6, 9 and 13 days. The data represent
mean"S.D. of triplicate determinations of one representative experiment out of two. ) P-0.05 vs. medium alone; ) ) P-0.01 vs. medium alone;
) ) ) P-0.001 vs. medium alone.
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 .and Prusoff see Methods . MEN 11066 was a very potent
inhibitor of human aromatase K s0.098"0.01 nM; nsi
.3 resulting at least 15-fold more active than the reference
 .compound anastrozole K s1.12 "0.03 nM; ns3 .i
 .MEN 11623 corresponding to the q enantiomer of MEN
11066 was at least 10-fold more active K s0.079"0.01i
.  . nM; ns3 than the y -MEN 11622 K s1.8"0.06i
.nM; ns3 .
3.2. Effects of estradiol, estrone, androstenedione and
( ) ( )testosterone on MCF-7 TA and MCF-7 hPA cell prolifer-
ation and DNA synthesis
The effects of steroid hormones on cell growth were
assayed on two different sublines originated from the
 .human breast carcinoma MCF-7: MCF-7 TA and MCF-
 .7 hPA .
In oestrogen-depleted medium, both cell lines were
sensitive to estradiol, but their proliferative responses were
 .different. MCF-7 TA cells were extremely dependent on
the presence of oestrogen in the medium: when subjected
to further 6 to 13 days of oestrogen deprivation, MCF-
 .7 TA cells were unable to grow. In the presence of
 .estradiol 0.01–100 nM , a significant cell number in-
crease was observed at 6 and 13 days from the beginning
 .of stimulation Fig. 2 . Estradiol response had the charac-
teristics of a bell-shaped curve with a peak response at 1
nM, producing a 23-fold increase in the cell number over
control.
 .On the other hand, MCF-7 hPA cells cultured in oe-
strogen-depleted medium for 14 days, after the pretreat-
ment period, did not show signs of suffering and even a
little proliferation was observed in a few cases. When
0.01–100 nM estradiol was added, an increase in cell
number was observed after 7-day stimulation only at a
concentration of 10 nM; after 14 days, the increase in cell
number was statistically significant at concentrations rang-
 .ing from 0.1 to 100 nM Fig. 3 . The maximum increase in
 .the MCF-7 hPA cell number was only about threefold
above control, indicating a lower sensitivity to estradiol-in-
 .duced proliferation, as compared to MCF-7 TA cells. In
general, the proliferative response, in terms of magnitude
 .  .Fig. 3. Effects of steroid hormones on human breast carcinoma MCF-7 hPA cell proliferation. MCF-7 hPA cells were plated at 30,000 cellsrwell and
 .stimulated in oestrogen-depleted medium with various concentrations 0.0001–100 nM of estradiol, estrone, testosterone and androstenedione. Incubation
 .medium was replaced twice a week. Cells were counted in a haemocytometer counting chamber Newbauer after 7 and 14 days. The data represent
mean"S.D. of triplicate determinations of one representative experiment out of two. ) P-0.05 vs. medium alone; ) ) P-0.01 vs. medium alone;
) ) ) P-0.001 vs. medium alone.
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Fig. 4. Effects of steroid hormones on DNA synthesis of human breast
 .  .  .carcinoma MCF-7 TA and MCF-7 hPA cells. MCF-7 TA and MCF-
 .7 hPA cells were plated at 25000 and 30000 cellsrwell, respectively,
 .and stimulated in oestrogen-depleted medium with estradiol 10 nM ,
 .  .androstenedione 100 nM and testosterone 100 nM . Incubation medium
was replaced twice a week. At the indicated time points, cells were
w3 xpulsed with H methyl-thymidine for 1 h and the incorporation in DNA
was then measured. The data represent mean"S.D. of triplicate determi-
nations. ) ) P -0.01 vs. medium alone; ) ) ) P -0.001 vs. medium alone.
 .of effect, triggered by steroids in MCF-7 hPA was less
 .that that observed in MCF-7 TA , suggesting that MCF-
 .7 hPA cells represent a phenotype of a more aggressive
steroid-independent breast tumour.
 .  .Both MCF-7 TA and MCF-7 hPA cells responded to
 .estrone too. As shown in Figs. 2 and 3, MCF-7 hPA cells
 .were more sensitive to estrone than MCF-7 TA cells; in
fact, a significant proliferation of the former was observed
with 0.1 nM estrone, whereas a 10-fold greater concentra-
tion of estrone was required to produce the same effect in
the latter.
Both testosterone and androstenedione-induced cell pro-
 .  .liferation in MCF-7 hPA Fig. 3 . A significant stimula-
 .tion was observed at high concentrations 10–100 nM for
both male sex hormones with a maximal response similar
to that observed with estradiol. The growth of the MCF-
 .7 TA cell line was stimulated by testosterone, but not by
 .androstenedione Fig. 2 . The stimulatory effect measured
at 100 nM testosterone, although consistently smaller than
that measured with the optimal estradiol concentration,
induced, however, a 10-fold increase in cell growth over
control.
In the presence of the estrogen-receptor competitor
 .tamoxifen 0.1 nM , the proliferative effects induced by
100 nM testosterone in both cell types were completely
 .inhibited data not shown . This indicated that cell prolifer-
ation induced by male sex hormones is mediated via
oestrogen receptor.
Fig. 5. Effects of aromatase inhibitors on testosterone-induced prolifera-
 .  .tion in human breast carcinoma MCF-7 TA and MCF-7 hPA cells.
 .  .MCF-7 TA and MCF-7 hPA cells were plated at 60,000 and 40,000
cellsrwell, respectively, and stimulated in oestrogen-depleted medium
 .with testosterone 100 nM . Variable concentrations of the aromatase
 .inhibitors 0.001–100 nM were coadministered with testosterone.
Medium was replaced twice a week. Cells were counted in a haemocy-
 .  .tometer counting chamber Newbauer after 12 days for MCF-7 TA and
 .13 days for MCF-7 hPA . Data are presented as % of response obtained
in cells stimulated with testosterone in the absence of aromatase in-
  .hibitors MCF-7 TA cellsrwell: 39,472"2311 and 408,083"42,754 for
 .unstimulated and testosterone-stimulated cells, respectively ns12 ;
 .MCF-7 hPA cellsrwell: 82,694"7531 and 236,305"20,658 for un-
 ..stimulated and testosterone-stimulated cells, respectively ns12 . The
data represent mean"S.D. of three independent experiments for each
aromatase inhibitor assayed.
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Table 1
Effects of aromatase inhibitors on testosterone-induced proliferation in
 .  .human breast carcinoma MCF-7 TA and MCF-7 hPA cells
w  .xAromatase inhibitors Cell lines IC nM50
 .  .MCF-7 TA MCF-7 hPA
MEN 11066 0.05"0.01 0.45"0.06
MEN 11622 0.05"0.02 0.57"0.15
MEN 11623 0.03"0.01 0.34"0.09
Anastrozole 1.2"0.5 7"4
 .  .MCF-7 TA and MCF-7 hPA cells were stimulated in oestrogen de-
 .pleted medium with testosterone 100 nM . Variable concentrations of
 .aromatase inhibitors 0.001–100 nM were coadministered with testos-
terone. Medium was replaced twice a week. Cells were counted in a
 .haemocytometer counting chamber Newbauer after 12 days for MCF-
 .  .7 TA and 13 days for MCF-7 hPA .
The results are expressed as IC values calculated with the computer50
program ALLFIT by simultaneous analysis of curves from three indepen-
dent experiments, each performed in triplicate.
 .The mitogenic effect of steroids in MCF-7 TA and
 .MCF-7 hPA cells was also confirmed by assessing the
stimulation of new DNA synthesis, measured as incorpora-
w3 x  .tion H methyl-thymidine Fig. 4 . In addition, it is worth
 .noting that the MCF-7 hPA cells, at variance with MCF-
 .7 TA cells, retain the ability to synthesize new DNA even
in the absence of steroids.
3.3. Effects of aromatase inhibitors on testosterone-induced
( ) ( )MCF-7 TA and MCF-7 hPA cell proliferation
The aromatase inhibitors anastrozole, MEN 11066,
MEN 11623 and MEN 11622 0.001–100 nM for each
.drugs , were assayed on cell proliferation induced by 100
nM testosterone. As shown in Fig. 5, all aromatase in-
hibitors were able to completely revert the testosterone-
 .induced cell proliferation both in MCF-7 TA and MCF-
 .7 hPA cells. On the contrary, none of them, even at 100
nM, did affect the growth of estradiol-stimulated cells
 .data not shown , indicating that the effect was not due to
aspecific toxicity but to a blockade of estronerestradiol
formation.
In both cell lines, anastrozole was less potent 1 to 2
.orders of magnitude than MEN 11066 and its enantiomers
that showed comparable activity. IC values indicated that50
 .MCF-7 TA cells are about 10-fold more sensitive to MEN
 .  .compounds than MCF-7 hPA cells Table 1 . When
 .MCF-7 hPA cell line was used, all the aromatase in-
hibitors assayed were also able to inhibit cell proliferation
induced by 100 nM androstenedione with comparable or
slightly greater potency IC values expressed in nM were50
0.15"0.008, 0.17"0.02, 0.09"0.02 and 9"3 for MEN
11066, MEN 11622, MEN 11623 and anastrozole, respec-
.tively, n s 3 than that measured with testosterone-
triggered response.
[3 ] ( )3.4. Con˝ersion of H androstenedione in MCF-7 TA
( )and MCF-7 hPA cells.
Aromatase activity was measured after 7, 24 or 48 h of
w3 xincubation of 200 nM H androstenedione with both cell
lines. Based on relative retention times of authentic stan-
dards processed in parallel, the described HPLC analysis
method allowed the determination of estrone, estradiol,
testosterone and 5a-androstanedione, besides androstene-
dione, in the incubation medium. The proportions of these
metabolites are reported in Table 2. The metabolism of
androstenedione was maximal after 24-h incubation, and
the most abundant metabolite detected with both cell lines,
was 5a-androstanedione, presumably formed because of a
 .high 5a-reductase activity Macaulay et al., 1994 . The
quantitative distribution of metabolites was different with
 .the two cell sublines used. With MCF-7 TA cells, rela-
tively low amounts of estradiol flanked estrone formation
 .in an approximate 1:1 ratio and no testosterone could be
 .detected. On the other hand, with MCF-7 hPA cells,
estradiol formed at a higher rate, being significantly more
abundant about sevenfold at all considered times, P-
Table 2
w3 xTime-dependent changes in the concentration of androstenedione and metabolites after incubation of H androstenedione with human breast carcinoma
 .  .MCF-7 TA and MCF-7 hPA cells
 .Cell subline Incubation N Analyte % relative amount
 .time h Androstenedione Estradiol Estrone Testosterone 5a-Androstane-
3,17-dione
 .MCF-7 TA 7 3 46.9"3.2 2.5"0.2 0.3"0.2 undetectable 46.2"0.1
24 3 18.1"1.9 3.6"0.2 2.5"0.7 undetectable 63.1"1.1
48 2 15.7"8.2 3.0"1.3 3.0"0.6 undetectable 51.9"1.1
 .MCF-7 hPA 7 3 41.2"1.8 6.1"2.3 undetectable undetectable 50.3"0.4
24 4 9.0"1.3 6.7"1.8 0.9"0.3 1.5"0.3 68.2"2.5
48 3 14.4"2.1 6.8"1.7 1.0"0.9 3.5"0.7 54.4"1.2
w3 xCells were incubated in the culture medium with 200 nM 7b- H androstenedione at 378C. At the indicated times, incubation medium was extracted thrice
with diethyl ether. Extracted steroids were analysed by radiodetector-coupled HPLC. The relative amount of each metabolite is calculated as the percent
ratio of the individual peak area to the total area of the five identified radioactive peaks. Data are expressed as mean values"S.D.
In a control experiment, tritiated androstenedione was incubated in the culture medium without cells for 7, 24 and 48 h. In these conditions, no metabolites
of androstenedione were detected.
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.0.01, Student t-test than estrone, that accumulated signifi-
 .  . .cantly P-0.01 less than with MCF-7 TA cells . Also
testosterone formation was measurable with these cells.
Overall, these data suggest a higher 17b-hydroxysteroid
 .dehydrogenase activity in MCF-7 hPA cells, as compared
 .to MCF-7 TA cells.
4. Discussion
The racemate compound MEN 11066 and its enan-
 .  .tiomers, q -MEN 11623 and y -MEN 11622, are new
potent aromatase inhibitors as demonstrated in the human
placental microsome assay. In addition, these compounds
were able to inhibit the androgen-dependent human breast
carcinoma cell proliferation confirming that blocking con-
version of androgens into oestrogen represents a suitable
therapeutic strategy in the treatment of oestrogen-depen-
 .dent tumours Brodie, 1991; Santen, 1991 . In view of the
fact that cell populations of human tumours are heteroge-
neous with respect to hormonal response, growth rate, drug
sensitivity and other biological characteristics according to
 .the evolutionary stage of the tumour Sutherland, 1988 ,
these differences should be taken into account when study-
ing the effects of anticancer drugs. For this reason, we
have characterized two sublines of the human breast carci-
noma MCF-7 as different models of oestrogen-dependent
tumour growth in which to evaluate the potency of aro-
matase inhibitors.
 .The first subline, named MCF-7 TA , was selected for
its ability to proliferate in the presence of testosterone; the
 .second one, named MCF-7 hPA , had been transfected
with the human placenta aromatase cDNA Zhou et al.,
.1990 , after recognizing that the parental cells had aro-
matase activity reduced to undetectable levels. Both cell
 .  .lines, MCF-7 TA and MCF-7 hPA , increased their pro-
liferative rate in the presence of estradiol and estrone.
 .However, MCF-7 TA cells were more sensitive than
 .MCF-7 hPA cells to estradiol-induced growth in terms of
effective concentration threshold, rapidity of response and
magnitude of effects. Responsiveness to testosterone was
 .also observed in both cell lines and, again, MCF-7 TA
subline was more sensitive in terms of magnitude of
response. The proliferation induced by testosterone was
blocked by aromatase inhibitors demonstrating the exis-
 .tence of an intrinsic aromatase activity in MCF-7 TA
cells. Also, the proliferative effects of androstenedione,
 .measurable only with MCF-7 hPA , can be attributed to its
conversion to oestrogen as demonstrated by the block
produced by aromatase inhibitors. These data, in accor-
dance with the blocking effect of tamoxifen, confirmed
that the cellular growth triggered by male sex hormones
was mediated by their conversion into oestrogen.
The measurement of the metabolites, formed after incu-
w3 xbation with H androstenedione, confirmed that aromatase
activity was present in both the cell lines, but the different
distribution of these metabolites helped in clarifying some
apparently conflicting data. In fact, both cell lines were
able to convert androstenedione into estrone; however,
 .MCF-7 hPA cells were able to convert estrone into estra-
diol and androstenedione into testosterone, while in MCF-
 .7 TA , cells, no production of testosterone was detected
and a consistent amount of estrone was not converted into
estradiol. These data indicate a higher activity of the
17b-hydroxysteroid dehydrogenase enzyme in the MCF-
 .7 hPA cells, which accounts for the comparable mitogenic
potency exerted by estrone and estradiol and also for their
responsiveness to both male sex hormones, androstene-
 .dione and testosterone. Instead, MCF-7 TA cells, al-
though able to correctly aromatize androstenedione into
estrone, were unable to consistently convert estrone and
androstenedione into estradiol and testosterone, respec-
tively. This was probably due to an impairment of the
17b-hydroxysteroid dehydrogenase enzyme. As a conse-
 .quence of that, MCF-7 TA cells were more responsive to
estradiol than estrone, and between the male sex hor-
mones, only testosterone acted as a growth factor. Al-
though estrone can directly interact with estrogen receptor,
similar to estradiol, higher concentrations of estrone were
required to have a measurable proliferative effect. In MCF-
 .7 TA cells, aromatase probably produces an amount of
 .estrone from androstenedione that is insufficient to reach
the concentration threshold for a proliferative effect, while
the amount of estradiol formed by testosterone aromatiza-
tion is efficacious in view of the lower concentration
 .required. Therefore, the MCF-7 TA unresponsiveness to
androstenedione is not related to a misfunction of the
tumour aromatase enzyme: this conclusion is in keeping
with the previous observation of no sequence difference of
aromatase gene expressed in human tumour cells in com-
parison with that of the enzyme expressed in placenta
 .Zhou et al., 1993 .
 .Thus, the MCF-7 TA subline used in this study is a
model of breast tumour extremely dependent from oestro-
gen for its growth and, therefore, the presence of an
intrinsic intratumoral aromatase activity represents an ad-
vantage for its sustenance. On the contrary, the scarce
 .oestrogen dependency shown by MCF-7 hPA cells and
the fact that they derived from cells that had lost intrinsic
 .aromatase activity Zhou et al., 1990 suggest that MCF-
 .7 hPA cells represent a more aggressive oestrogen-inde-
pendent breast tumour phenotype with no need for aro-
matase activity. The peculiar characteristics of these cell
lines have given us the opportunity to evaluate the role and
efficacy of aromatase inhibitors in oestrogen-dependent
proliferation of two different tumour models.
The MEN aromatase inhibitors were able to completely
inhibit in a concentration-dependent manner, testosterone-
 .triggered proliferation both with MCF-7 TA and MCF-
 .7 hPA cells, while they did not affect the estradiol-in-
duced cell growth, as a proof of their specificity for the
aromatase enzyme. These data, while showing evidence of
( )C. Palma et al.rEuropean Journal of Pharmacology 409 2000 93–101 101
the biological relevance of aromatase in breast cancer
proliferation, highlight also the ability of aromatase in-
hibitors to effectively contrast the functionality of intratu-
moural aromatase, either intrinsic or of placental origin.
MEN 11066 and its enantiomers showed comparable
activity in both systems, MEN 11623 being only slightly
more potent. However, it was at least ten times more
potent than MEN 11622 in inhibiting purified human
placenta aromatase. The different experimental conditions,
including the long-lasting exposure of these compounds to
biological media during proliferation assays, may be the
cause of these differences in potencies. In fact, racemiza-
tion of the enantiomers could occur in the medium where
the cells are grown and, as a consequence, differences in
activity between them may be lowered. If racemization
occurs not only in this in vitro cell culture condition but
also in vivo, the separation of enantiomers may not be
mandatory for developing these drugs. In any case, the
MEN aromatase inhibitors were found to be markedly
more potent than anastrozole, a drug currently marketed
 .Buzdar et al., 1996; Harper-Wynne and Coombes, 1999 .
Interestingly, the values of IC calculated for all the50
 .aromatase inhibitors assayed, indicated that MCF-7 TA
 .are more sensitive than MCF-7 hPA to these compounds.
 .The greater sensitivity of MCF-7 TA cells may be related
to their greater sensitivity to oestrogen-dependent growth,
although, we cannot rule out the presence of a lower
amount of aromatase enzyme per cell. When using MCF-
 .7 hPA cells, in which aromatase has been artificially
overexpressed and the cells are transforming into a more
aggressive oestrogen-independent tumour phenotype, the
potency of aromatase inhibitors might be underestimated.
The data suggest that the anticancer treatment with
aromatase inhibitors may be extremely efficient in tumours
highly responsive to oestrogen, as occurs in the early phase
of breast cancer, supporting the possibility to use aro-
matase inhibitors in both neo-adjuvant and chemopreven-
 .tive setting Kelloff et al., 1998; Lubet et al., 1998 .
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